Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).

Lauren Julia Brown,Alison Weppler,Prachi Bhave,Clara Allayous,James Randall Patrinely,Patrick A. Ott,Shahneen Sandhu,Andrew Haydon,Celeste Lebbe,Douglas B. Johnson,Georgina V. Long,Alexander M. Menzies,Matteo S. Carlino

Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).

2020

Lauren Julia Brown
Alison Weppler
Prachi Bhave
Clara Allayous
James Randall Patrinely
Patrick A. Ott
Shahneen Sandhu
Andrew Haydon
Celeste Lebbe
Douglas B. Johnson
Georgina V. Long
Alexander M. Menzies
Matteo S. Carlino

10026Background: Clinical trials of immunotherapy exclude patients (pts) with pre-existing AD. While retrospective data exist regarding the efficacy and safety of single agent ipi and anti-PD1 anti...

Keywords:

Oncology
anti pd 1
Ipilimumab
Internal medicine
advanced melanoma
in patient
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations